Completed NA INTERVENTIONAL 2-arm NCT06528600

Comparative Study of Two Hyaluronic Acid Formulation in the Management of Knee Osteoarthritis

A Randomized, Double-Blind, Active Controlled, Multi-Center, Non- Inferiority Study of One-injection of Hymovis ONE (32 mg/4ml) Against Currently Approved 1-injection Regimen of Monovisc in Symptomatic Relief of Osteoarthritis of the Knee

Sponsor: Fidia Farmaceutici s.p.a.

Conditions Osteoarthritis, Knee

Interventions Hymovis ONE Monovisc

Updated 3 times since 2024 Last updated: Jul 26, 2024 Started: Sep 16, 2020 Primary completion: Mar 15, 2024 Completion: Jun 15, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Osteoarthritis, Knee and is currently completed. Fidia Farmaceutici s.p.a. leads this study, which shows 3 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

3 versions recorded

Sep 2025 — Present [monthly]

Completed NA
Sep 2024 — Sep 2025 [monthly]

Completed NA
Aug 2024 — Sep 2024 [monthly]

Completed NA

First recorded

Sep 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fidia Farmaceutici s.p.a.

Data source: Fidia Farmaceutici s.p.a.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Borgo Val di Taro, Italy , Brescia, Italy , Caserta, Italy , Conegliano, Italy , Cuneo, Italy , Esine, Italy , Maddaloni, Italy , Napoli, Italy , Novara, Italy , Parma, Italy and 3 more locations